Big Cypress (BCYP) to Combine with SAB Biotherapeutics in $325M Deal

big-cypress-sab logo

Big Cypress (BCYP) to Combine with SAB Biotherapeutics in $325M Deal


Warning: DOMDocument::loadHTML(): Unexpected end tag : p in Entity, line: 5 in /var/convesio/wordpress/wp-content/plugins/spacinsider-upqode/src/Start.php on line 90

Big Cypress Acquisition Corp. (NASDAQ:BCYP) has entered into a definitive agreement to combine with clinical-stage biopharmaceutical company SAB Biotherapeutics at an enterprise value of $325 million. Sioux Falls-based SAB Biotherapeutics utilizes advanced genetic engineering and antibody science to develop antibodies that target specific diseases, such as COVID-19. The company’s platform rapidly produces natural, high-potency, human
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.